Fresenius buys remaining 45% of mAbxience for up to EUR 750 million

• Fresenius bought the remaining 45% of biosimilars company mAbxience, taking full ownership of the platform within Fresenius Kabi Biopharma.
• Total consideration up to EUR 750 million cash, including a EUR 50 million contingent payment tied to site approvals.
• Deal was signed and completed on Sept. 30, 2026; no regulatory approvals were required.
• Funding came from existing liquidity and operating cash flow; net debt to EBITDA expected to rise by about 20 basis points.
• Transaction expected to be immediately accretive to group core earnings per share from completion; 2026 guidance unchanged.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fresenius SE & Co. KGaA published the original content used to generate this news brief on October 01, 2026, and is solely responsible for the information contained therein.